In a phase II clinical trial (NCT01795768), AZD4547 showed therapeutic efficacy as a second-line treatment in patients with FGFR1- and FGFR2-amplified breast cancer, squamous cell carcinoma of the lung, or gastro-esophageal adenocarcinoma. Here, FGFR1 is linked to breast carcinoma.